|Mr. Blake Wise||CEO & Director||644k||N/A||1971|
|Dr. Kenneth J. Hillan||Pres, Director and Pres of R&D||771.6k||N/A||1961|
|Mr. Tobin C. Schilke||Chief Financial Officer||N/A||N/A||1975|
|Dr. Lee Swem||Chief Scientific Officer||N/A||N/A||1976|
|Mr. Gary Loeb||Gen. Counsel, Corp. Sec. & Chief Compliance Officer||N/A||N/A||1970|
Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Achaogen, Inc.’s ISS Governance QualityScore as of August 1, 2018 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 7.